Advertisement

Imaging of tau deposits in adults with Niemann-Pick type C disease: a case-control study

  • Victor L. VillemagneEmail author
  • D. Velakoulis
  • V. Doré
  • S. Bozinoski
  • C. L. Masters
  • C. C. Rowe
  • Mark WalterfangEmail author
Original Article

Abstract

Purpose

Niemann-Pick type C (NPC) is a cholesterol storage disease characterized by disruption in the endosomal–lysosomal transport system that leads to the accumulation of cholesterol and glycolipids in lysosomes. Developmental cognitive delay and progressive motor and cognitive impairment are characteristic of the disease. Tau accumulation has been reported in some NPC patients. We investigated the presence of tau and Aβ-amyloid deposits in a group of NPC patients and for comparison in age-matched healthy controls (HC).

Methods

Eight NPC patients and seven HC were included in the study. Participants underwent tau imaging with 18F-AV1451 and amyloid imaging with 11C-PiB. Both 18F-AV1451 and 11C-PiB standardized uptake value ratios were generated using the cerebellar cortex as the reference region. Associations between imaging results, and clinical and neurocognitive parameters were assessed through nonparametric analyses.

Results

All participants were Aβ-negative. Four NPC patients presented with high tau burden in the brain. A 21-year-old female patient and a 40-year-old male patient showed high neocortical tau burden in a pattern different from that observed in patients with Alzheimer’s disease, while the same 40-year-old male patient, a 40-year-old female patient and a 50-year-old female patient showed high regional tau burden in the mesial temporal cortex. Spearman’s correlation analysis showed an association between tau burden in the mesial temporal lobe and age (p = 0.022), and age at symptom onset (p = 0.009), and between frontotemporal tau and duration of symptoms (p = 0.027). There were no correlations between global and regional tau and cognitive parameters.

Conclusion

Four of eight NPC patients showed tau deposition in the brain. The results of our exploratory study suggest that while tau deposits do not affect cognitive performance, tau deposits are associated with measures of disease onset and progression. Further studies in a larger cohort of NPC patients are needed to confirm these initial findings.

Keywords

Niemann-Pick type C disease Tau pathology Tau imaging Amyloid imaging Cognitive impairment Disease severity 

Notes

Acknowledgments

We thank Avid Radiopharmaceuticals for providing AV1451 precursor and standard, especially Drs. Michael Pontecorvo and Michael Devous, for kindly providing 18F-AV1451 images of three young adults used for age-matched comparison with young NPC patients. We also thank Dr. Graeme O’Keefe, Dr. Gordon Chan, Dr. Kenneth Young, Dr. Sylvia Gong, Mrs. Denise El-Sheikh; and the Brain Research Institute for their assistance with this study.

Author contributions

V.L.V. and M.W. conceived and designed the research. V.L.V., M.W., D.V., V.D., S.B., C.L.M. and C.C.R. performed the research and participated in the drafting of the work and revising it critically for important intellectual content. V.L.V. and M.W. wrote the paper with input from all authors.

Funding

This work was supported in part by the Austin Hospital Medical Research Foundation. The funding source was not involved in the study design, in the collection, analysis and interpretation of the data, in the writing of the report, or in the decision to submit the paper for publication.

Compliance with ethical standards

Conflicts of interest

None.

References

  1. 1.
    Carstea ED, Morris JA, Coleman KG, Loftus SK, Zhang D, Cummings C, et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science. 1997;277(5323):228–31.CrossRefGoogle Scholar
  2. 2.
    Naureckiene S, Sleat DE, Lackland H, Fensom A, Vanier MT, Wattiaux R, et al. Identification of HE1 as the second gene of Niemann-Pick C disease. Science. 2000;290(5500):2298–301.  https://doi.org/10.1126/science.290.5500.2298.CrossRefPubMedGoogle Scholar
  3. 3.
    Wassif CA, Cross JL, Iben J, Sanchez-Pulido L, Cougnoux A, Platt FM, et al. High incidence of unrecognized visceral/neurological late-onset Niemann-Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets. Genet Med. 2016;18(1):41–8.  https://doi.org/10.1038/gim.2015.25.CrossRefPubMedGoogle Scholar
  4. 4.
    Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F, et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab. 2012;106(3):330–44.  https://doi.org/10.1016/j.ymgme.2012.03.012.CrossRefPubMedGoogle Scholar
  5. 5.
    Walkley SU, Suzuki K. Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim Biophys Acta. 2004;1685(1-3):48–62.  https://doi.org/10.1016/j.bbalip.2004.08.011.CrossRefPubMedGoogle Scholar
  6. 6.
    March P, Thrall M, Brown D, Mitchell T, Lowenthal A, Walkley S. GABAergic neuroaxonal dystrophy and other cytopathological alterations in feline Niemann-Pick disease type C. Acta Neuropathol. 1997;94:164–72.CrossRefGoogle Scholar
  7. 7.
    Ong W, Kumar U, Switzer R, Sidhu A, Suresh G, Hu C, et al. Neurodegeneration in Niemann-Pick type C disease mice. Exp Brain Res. 2001;141:218–31.CrossRefGoogle Scholar
  8. 8.
    Paul C, Boegle A, Maue R. Before the loss: neuronal dysfunction in Niemann-Pick type C disease. Biochim Biophys Acta. 2004;1685:63–76.CrossRefGoogle Scholar
  9. 9.
    Fan Q-W, Yu W, Gong J-S, Zou K, Sawamura N, Senda T, et al. Cholesterol-dependent modulation of dendrite outgrowth and microtubule stability in cultured neurons. J Neurochem. 2002;80:178–90.CrossRefGoogle Scholar
  10. 10.
    Sakamoto H, Ukena K, Tsutsu K. Effects of progesterone synthesized de novo in the developing Purkinje cell on its dendritic growth and synaptogenesis. J Neurosci. 2001;16:6221–32.CrossRefGoogle Scholar
  11. 11.
    Walterfang M, Abel LA, Desmond P, Fahey MC, Bowman EA, Velakoulis D. Cerebellar volume correlates with saccadic gain and ataxia in adult Niemann-Pick type C. Mol Genet Metab. 2013;108(1):85–9.  https://doi.org/10.1016/j.ymgme.2012.11.009.CrossRefPubMedGoogle Scholar
  12. 12.
    Walterfang M, Fahey M, Desmond P, Wood A, Seal ML, Steward C, et al. White and gray matter alterations in adults with Niemann-Pick disease type C: a cross-sectional study. Neurology. 2010;75(1):49–56.  https://doi.org/10.1212/WNL.0b013e3181e6210e.CrossRefPubMedGoogle Scholar
  13. 13.
    Walterfang M, Patenaude B, Abel LA, Kluenemann H, Bowman EA, Fahey MC, et al. Subcortical volumetric reductions in adult Niemann-Pick disease type C: a cross-sectional study. AJNR Am J Neuroradiol. 2013;34(7):1334–40.  https://doi.org/10.3174/ajnr.A3356.CrossRefPubMedGoogle Scholar
  14. 14.
    Horoupian DS, Yang SS. Paired helical filaments in neurovisceral lipidosis (juvenile dystonic lipidosis). Ann Neurol. 1978;4(5):404–11.  https://doi.org/10.1002/ana.410040504.CrossRefPubMedGoogle Scholar
  15. 15.
    Auer IA, Schmidt ML, Lee VM, Curry B, Suzuki K, Shin RW, et al. Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease. Acta Neuropathol. 1995;90(6):547–51.CrossRefGoogle Scholar
  16. 16.
    Love S, Bridges LR, Case CP. Neurofibrillary tangles in Niemann-Pick disease type C. Brain. 1995;118(Pt 1):119–29.CrossRefGoogle Scholar
  17. 17.
    Suzuki K, Parker CC, Pentchev PG, Katz D, Ghetti B, D'Agostino AN, et al. Neurofibrillary tangles in Niemann-Pick disease type C. Acta Neuropathol. 1995;89(3):227–38.CrossRefGoogle Scholar
  18. 18.
    Zhang M, Li J, Chakrabarty P, Bu B, Vincent I. Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick type C mice. Am J Pathol. 2004;165(3):843–53.CrossRefGoogle Scholar
  19. 19.
    Chiba Y, Komori H, Takei S, Hasegawa-Ishii S, Kawamura N, Adachi K, et al. Niemann-Pick disease type C1 predominantly involving the frontotemporal region, with cortical and brainstem Lewy bodies: an autopsy case. Neuropathology. 2014;34(1):49–57.  https://doi.org/10.1111/neup.12047.CrossRefPubMedGoogle Scholar
  20. 20.
    Bergeron D, Poulin S, Laforce R Jr. Cognition and anatomy of adult Niemann-Pick disease type C: insights for the Alzheimer field. Cogn Neuropsychol. 2018;35(3-4):209–22.CrossRefGoogle Scholar
  21. 21.
    Bu B, Klunemann H, Suzuki K, Li J, Bird T, Jin LW, et al. Niemann-Pick disease type C yields possible clue for why cerebellar neurons do not form neurofibrillary tangles. Neurobiol Dis. 2002;11(2):285–97.CrossRefGoogle Scholar
  22. 22.
    Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14(4):225–36.CrossRefGoogle Scholar
  23. 23.
    Walterfang M, Siu R, Velakoulis D. The NUCOG: validity and reliability of a brief cognitive screening tool in neuropsychiatric patients. Aust N Z J Psychiatry. 2006;40(11–12):995–1002.  https://doi.org/10.1111/j.1440-1614.2006.01923.x.CrossRefPubMedGoogle Scholar
  24. 24.
    Iturriaga C, Pineda M, Fernandez-Valero EM, Vanier MT, Coll MJ. Niemann-Pick C disease in Spain: clinical spectrum and development of a disability scale. J Neurol Sci. 2006;249(1):1–6.  https://doi.org/10.1016/j.jns.2006.05.054.CrossRefPubMedGoogle Scholar
  25. 25.
    Villemagne V, Dore V, Bourgeat P, Burnham S, Mulligan R, Laws S, et al. The Tau MeTeR composites for the generation of continuous and categorical measures of tau deposits in the brain. J Mol Med Ther. 2017;1(1):25–9.Google Scholar
  26. 26.
    Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351–7.CrossRefGoogle Scholar
  27. 27.
    Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016;139(Pt 5):1551–67.  https://doi.org/10.1093/brain/aww027.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Marquie M, Siao Tick Chong M, Anton-Fernandez A, Verwer EE, Saez-Calveras N, Meltzer AC, et al. [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging. Acta Neuropathol. 2017;134(4):619–28.  https://doi.org/10.1007/s00401-017-1740-8.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Scholl M, Ossenkoppele R, Strandberg O, Palmqvist S, Swedish Bio F, Jogi J, et al. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease. Brain. 2017;140(9):2286–94.  https://doi.org/10.1093/brain/awx171.CrossRefPubMedGoogle Scholar
  30. 30.
    Zhang M, Wang X, Jiang F, Wang W, Vincent I, Bu B. Mitotic epitopes are incorporated into age-dependent neurofibrillary tangles in Niemann-Pick disease type C. Brain Pathol. 2010;20(2):367–77.CrossRefGoogle Scholar
  31. 31.
    Ono M, Sahara N, Kumata K, Ji B, Ni R, Koga S, et al. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain. 2017;140(3):764–80.  https://doi.org/10.1093/brain/aww339.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Fan QW, Yu W, Senda T, Yanagisawa K, Michikawa M. Cholesterol-dependent modulation of tau phosphorylation in cultured neurons. J Neurochem. 2001;76(2):391–400.CrossRefGoogle Scholar
  33. 33.
    Sawamura N, Gong JS, Chang TY, Yanagisawa K, Michikawa M. Promotion of tau phosphorylation by MAP kinase Erk1/2 is accompanied by reduced cholesterol level in detergent-insoluble membrane fraction in Niemann-Pick C1-deficient cells. J Neurochem. 2003;84(5):1086–96.CrossRefGoogle Scholar
  34. 34.
    Distl R, Meske V, Ohm TG. Tangle-bearing neurons contain more free cholesterol than adjacent tangle-free neurons. Acta Neuropathol. 2001;101(6):547–54.PubMedGoogle Scholar
  35. 35.
    Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140(3):748–63.  https://doi.org/10.1093/brain/aww334.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Buckley RF, Hanseeuw B, Schultz AP, Vannini P, Aghjayan SL, Properzi MJ, et al. Region-specific association of subjective cognitive decline with tauopathy independent of global beta-amyloid burden. JAMA Neurol. 2017;74(12):1455–63.CrossRefGoogle Scholar
  37. 37.
    Cho H, Chooi J, Lee S, Hwang M, Ryu Y, Lee M, et al. Tau burden and cognition in early-onset versus late-onset Alzheimer’s disease spectrum. Alzheimers Dement. 2016;12(7):S711–2.CrossRefGoogle Scholar
  38. 38.
    Mattsson N, Zetterberg H, Bianconi S, Yanjanin NM, Fu R, Mansson JE, et al. Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Neurology. 2011;76(4):366–72.  https://doi.org/10.1212/WNL.0b013e318208f4ab.CrossRefPubMedGoogle Scholar
  39. 39.
    Mattsson N, Zetterberg H, Bianconi S, Yanjanin NM, Fu R, Mansson JE, et al. Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in Niemann-Pick type C. JIMD Rep. 2012;3:45–52.  https://doi.org/10.1007/8904_2011_47.CrossRefPubMedGoogle Scholar
  40. 40.
    Matsuo M, Shraishi K, Wada K, Ishitsuka Y, Doi H, Maeda M, et al. Effects of intracerebroventricular administration of 2-hydroxypropyl-beta-cyclodextrin in a patient with Niemann-Pick type C disease. Mol Genet Metab Rep. 2014;1:391–400.  https://doi.org/10.1016/j.ymgmr.2014.08.004.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Bu B, Li J, Davies P, Vincent I. Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J Neurosci. 2002;22(15):6515–25.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Molecular Imaging & Therapy, Centre for PETAustin HealthHeidelbergAustralia
  2. 2.The Florey Institute of Neuroscience and Mental HealthThe University of MelbourneMelbourneAustralia
  3. 3.Department of Medicine, Austin HealthThe University of MelbourneMelbourneAustralia
  4. 4.Neuropsychiatry Unit, Royal Melbourne Hospital & Melbourne Neuropsychiatry CentreUniversity of MelbourneMelbourneAustralia
  5. 5.CSIRO Preventative Health Flagship: The Australian e-Health Research Centre – MelbourneMelbourneAustralia

Personalised recommendations